STOCK TITAN

Evogene - EVGN STOCK NEWS

Welcome to our dedicated page for Evogene news (Ticker: EVGN), a resource for investors and traders seeking the latest updates and insights on Evogene stock.

Overview

Evogene (EVGN) is a pioneering computational biology company that leverages big data, artificial intelligence, and deep scientific insights to revolutionize the development of life-science-based products. Operating at the convergence of biotechnology and computational analytics, the company focuses on creating breakthrough solutions in agriculture, human health, and industrial applications. With its roots in advanced plant genomics research, Evogene integrates proprietary tech-engines and innovative predictive platforms to enhance seed traits and crop productivity.

Core Business Model and Technologies

At the heart of Evogene’s operations is its unique technology infrastructure composed of three distinct tech-engines: MicroBoost AI, ChemPass AI, and GeneRator AI. These platforms allow the company to systematically accelerate the discovery and development of novel products by targeting and optimizing key components such as microbes, small molecules, and genetic elements. This multi-engine approach not only reduces development time and costs but also increases the probability of success through sophisticated computational predictive biology.

Market Position and Strategic Collaborations

Evogene operates in the high-stakes arena of life sciences, where precision and innovation drive competitive advantage. The company addresses challenges in agricultural productivity by improving seed traits related to yield enhancement and stress tolerance. Its strategic collaborations with world-leading agricultural firms underscore its role as an unbiased, research-driven innovator in the sector. These partnerships facilitate the development of advanced ag-biological products, which include bio-inoculants and seed treatments that are designed to address both biotic and abiotic stresses in crops such as corn, soybean, wheat, and rice.

Diverse Subsidiary Operations

Evogene’s business model is diversified through its subsidiaries, each specializing in a niche area within the life sciences:

  • Lavie Bio Ltd. focuses on developing microbiome-based ag-biologicals and innovative bio-stimulant products using the MicroBoost AI tech-engine, enhancing crop vigor and stress tolerance.
  • Biomica Ltd. is dedicated to creating human microbiome-based therapeutics, harnessing the capabilities of its computational platforms to address complex medical challenges.
  • AgPlenus Ltd. utilizes ChemPass AI to design next-generation agricultural chemicals, supporting sustainable and effective crop protection measures.
  • Casterra Ag Ltd. commercializes elite castor seed varieties for biofuel and biopolymer production, making use of GeneRator AI to optimize plant genomics for industrial applications.

Technology-Driven Innovation and Operational Excellence

Evogene’s approach is deeply rooted in an advanced understanding of computational predictive biology. By leveraging its proprietary platforms and extensive datasets, the company is able to pinpoint genetic elements and microbial candidates that directly contribute to improved agricultural outputs. Its innovative use of artificial intelligence and big data analytics has allowed for rapid prototyping of solutions, which are then validated through extensive field trials and strategic partnerships. This methodical integration of technology into the research and development process affirms its commitment to reducing time-to-market while ensuring product efficacy and sustainability.

Competitive Landscape and Industry Significance

Within the rapidly evolving fields of computational biology and ag-biotechnology, Evogene distinguishes itself by combining deep domain expertise with technology-driven innovation. Unlike conventional approaches that rely on traditional trial-and-error methods, Evogene’s integrated strategy is designed to systematically inform product development, thereby minimizing risks while maximizing innovative output. Its successful collaborations with established industry players position Evogene as an authoritative resource in product design and predictive biology.

Key Industry Terminology and Concepts

The company’s operations are underpinned by several industry-specific terminologies that resonate with experts in the field:

  • Computational predictive biology: Utilizing algorithms and large data sets to model and predict biological outcomes.
  • Proprietary tech-engines: Engineered platforms such as MicroBoost AI, ChemPass AI, and GeneRator AI that incorporate multidisciplinary expertise.
  • Plant genomics: The scientific study of plants at the molecular level, which is critical to enhancing desirable seed traits.
  • Ag-biologicals and ag-chemicals: Products designed to improve crop resilience and productivity, often replacing traditional chemical inputs.

Conclusion

Evogene stands as an exemplar of how cutting-edge technology can drive advancements in the life-science sector. By integrating deep scientific research with sophisticated AI-driven platforms, the company not only improves agricultural outputs but also paves the way for innovative solutions in human therapeutics and industrial applications. Its diverse portfolio, strategic collaborations, and focus on continuous innovation have firmly established its reputation as a dynamic, forward-thinking entity in the competitive landscape of computational biology.

Rhea-AI Summary
Lavie Bio Ltd., a subsidiary of Evogene Ltd., partners with Ceres Global Ag Corp. to integrate its bio-inoculant, YalosTM, into regenerative agriculture initiatives in the USA and Canada. Ceres aims to enhance sustainability and productivity in the agricultural industry through this collaboration.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.1%
Tags
none
-
Rhea-AI Summary
Evogene Ltd. announces financial results for Q4 and full-year 2023, showcasing revenue growth and successful collaborations. The company's AI tech-engines drive partnerships with industry leaders, leading to revenue streams and expanding sales. Evogene's subsidiaries achieve significant milestones in various sectors, reflecting a positive outlook for 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.23%
Tags
-
Rhea-AI Summary
AgPlenus Ltd., a subsidiary of Evogene Ltd., achieves a milestone in collaboration with Corteva Agriscience for novel herbicides. The successful identification of a new family of molecules with herbicidal effect through a novel Mode of Action marks a significant development in addressing weed resistance challenges in the agricultural industry.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.12%
Tags
none
Rhea-AI Summary
Casterra Ag Ltd., a subsidiary of Evogen Ltd., signed strategic agreements with seed producers in Brazil and Africa to enhance castor seed production, adding 400 tons in 2024. The agreements aim to establish long-term production infrastructure and lower production risks by expanding geographies of seed producers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.03%
Tags
none
-
Rhea-AI Summary
Lavie Bio Ltd., a subsidiary of Evogene Ltd., secures $2.5 million as the second-half advance payment under the licensing agreement with Corteva, completing a total $5 million advance payment. The agreement grants Corteva exclusive rights to develop and commercialize bio-fungicide products targeting fruit rots and powdery mildew. Lavie Bio will receive future milestone payments and royalties from Corteva's sales.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Evogene Ltd. (EVGN) to release financial results for Q3 2023 on March 7th, 2024. Conference call scheduled for 9:00 AM ET. Company aims to revolutionize life-science product discovery and development. Replay and webcast details provided for investor access.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.12%
Tags
Rhea-AI Summary
AgPlenus Ltd, a subsidiary of Evogene Ltd., appoints Dr. Dan Jacob Gelvan as CEO, bringing extensive experience in science and technology sectors. Dr. Gelvan's leadership aims to drive growth and innovation in sustainable crop protection products.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.23%
Tags
management
-
Rhea-AI Summary
AgPlenus Ltd., a subsidiary of Evogene Ltd., collaborates with Bayer AG to develop a sustainable herbicide using AI technology. The collaboration aims to address weed resistance challenges in agriculture by designing a novel Mode-of-Action herbicide targeting the APTH1 protein.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
22.37%
Tags
none
-
Rhea-AI Summary
Syngenta Crop Protection and Lavie Bio Ltd., a subsidiary of Evogene Ltd., announce a collaboration to develop new biological insecticidal solutions to combat global crop challenges caused by insects. The agreement combines Lavie Bio's technology platform with Syngenta's research and commercialization capabilities to address the $70 billion annual economic impact of insect damage on crops.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.33%
Tags
partnership
Rhea-AI Summary
Evogene Ltd. (EVGN) and Verb Biotics LLC. have entered into a collaboration agreement to develop new strains of probiotic bacteria that produce highly sustainable quantities of microbial metabolites, aiming to improve human health and vitality. The probiotics market is expected to double and reach approximately $114 billion by 2031, creating significant opportunities for growth. The financial terms of the agreement are not disclosed. The collaboration combines Evogene's tech-engine MicroBoost AI with Verb Biotic's access to the genomes of various microbial strains, generating excellent synergy. The collaboration underscores Evogene's strategic commitment to leveraging AI tech-engines in new areas and opens doors for additional sectors in the life sciences industry to benefit from their powerful technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.56%
Tags
none

FAQ

What is the current stock price of Evogene (EVGN)?

The current stock price of Evogene (EVGN) is $1.05 as of April 15, 2025.

What is the market cap of Evogene (EVGN)?

The market cap of Evogene (EVGN) is approximately 7.1M.

What is Evogene's core business?

Evogene is a computational biology company that uses artificial intelligence and big data to develop innovative life-science products, including advanced solutions for agriculture and human health.

What proprietary technologies does Evogene use?

The company has developed three unique tech-engines—MicroBoost AI, ChemPass AI, and GeneRator AI—which are used to optimize the discovery and development of products based on microbes, small molecules, and genetic elements.

How does Evogene contribute to agricultural productivity?

Through its deep understanding of plant genomics and strategic partnerships, Evogene enhances seed traits, develops bio-inoculant products, and optimizes crop resistance to biotic and abiotic stresses.

What are Evogene's main market segments?

Evogene operates in multiple segments including agriculture, human therapeutics, and industrial applications, leveraging its AI-driven platforms to address diverse market needs.

Who are Evogene's key subsidiaries?

Evogene's portfolio includes Lavie Bio for ag-biologicals, Biomica for human microbiome-based therapeutics, AgPlenus for ag-chemicals, and Casterra Ag for advanced castor seed cultivation.

How does Evogene's technology reduce development time and cost?

By integrating computational predictive biology with big data analytics, Evogene’s platforms streamline product discovery and optimization, significantly cutting down on both time and cost during development.

What differentiates Evogene from other biotech companies?

Evogene’s unique integration of AI-driven tech-engines with deep scientific expertise in plant genomics and life sciences sets it apart, enabling more accurate predictions and faster development cycles.

How does Evogene maintain its competitive edge in the industry?

Through strategic collaborations, continuous innovation, and a diversified portfolio of subsidiaries, Evogene positions itself as an authoritative and trusted partner in the development of life-science products.
Evogene

Nasdaq:EVGN

EVGN Rankings

EVGN Stock Data

7.14M
6.59M
1.56%
7.68%
0.51%
Biotechnology
Healthcare
Link
Israel
Rehovot